The glial activation inhibitor AV411 reduces morphine-induced nucleus accumbens dopamine release.
Glial activation has recently been discovered to modulate several effects of morphine, including analgesia, tolerance, and dependence. The present studies extend this line of investigation by exploring whether glial activation may also affect extracellular levels of dopamine (DA) in the nucleus accumbens (NAc) shell, a neurochemical corollary of morphine-induced drug reward, during a challenge dose of morphine in experiments both with and without precipitated withdrawal. Morphine or vehicle was administered s.c. for 4 days (starting at 15 mg/kg/day up to 20 mg/kg/day), and the glial activation inhibitor AV411 (7.5 mg/kg) or vehicle was administered twice daily. A challenge dose of morphine (22.5 mg/kg) or saline was then given during dialysis. In the first experiment, naloxone (10 mg/kg) was administered 1h after morphine during dialysis in AV411- or vehicle-treated rats, and behavioral signs of somatic withdrawal were assessed during microdialysis. In the second experiment, using the same dosing regimen, sampling continued 3 h after morphine or saline in AV411- or vehicle-treated rats. NAc DA increased in vehicle-treated rats significantly more than in AV411-treated rats before naloxone treatment, and withdrawal symptoms were significantly reduced in AV411-treated rats. The decrease in morphine-induced NAc DA by AV411 was persistent, lasting 3+h post-morphine. These results indicate that glial activation contributes to the effects of morphine on NAc DA, which is associated with somatic signs of precipitated withdrawal.
Bland
Sondra T
ST
Department of Psychology & Center for Neuroscience, Campus Box 345, University of Colorado at Boulder, Boulder, CO 80309-0345, USA. sondra.bland@colorado.edu
Hutchinson
Mark R
MR
Maier
Steven F
SF
Watkins
Linda R
LR
Johnson
Kirk W
KW
D000704:Analysis of Variance; D000818:Animals; D001522:Behavior, Animal; D002851:Chromatography, High Pressure Liquid; D004298:Dopamine / Q000378:metabolism*; D004334:Drug Administration Schedule; D007274:Injections, Intraperitoneal; D008297:Male; D017551:Microdialysis; D009020:Morphine / Q000008:administration & dosage*; D009021:Morphine Dependence; D009270:Naloxone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009294:Narcotics / Q000008:administration & dosage; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism*; D009714:Nucleus Accumbens / Q000187:drug effects* / Q000378:metabolism; D011725:Pyridines / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013375:Substance Withdrawal Syndrome / Q000378:metabolism; D007212:Indolizines; D011720:Pyrazoles
D004298:Dopamine; D009020:Morphine; D009270:Naloxone; D009292:Narcotic Antagonists; D009294:Narcotics; D011725:Pyridines; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles